Cargando…

Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives

BACKGROUND: Wolfram syndrome (WS), a rare genetic disorder, is considered the best prototype of endoplasmic reticulum (ER) diseases. Classical WS features are childhood-onset diabetes mellitus, optic atrophy, deafness, diabetes insipidus, neurological signs, and other abnormalities. Two causative ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallotta, Maria Teresa, Tascini, Giorgia, Crispoldi, Roberta, Orabona, Ciriana, Mondanelli, Giada, Grohmann, Ursula, Esposito, Susanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651977/
https://www.ncbi.nlm.nih.gov/pubmed/31337416
http://dx.doi.org/10.1186/s12967-019-1993-1
_version_ 1783438469928845312
author Pallotta, Maria Teresa
Tascini, Giorgia
Crispoldi, Roberta
Orabona, Ciriana
Mondanelli, Giada
Grohmann, Ursula
Esposito, Susanna
author_facet Pallotta, Maria Teresa
Tascini, Giorgia
Crispoldi, Roberta
Orabona, Ciriana
Mondanelli, Giada
Grohmann, Ursula
Esposito, Susanna
author_sort Pallotta, Maria Teresa
collection PubMed
description BACKGROUND: Wolfram syndrome (WS), a rare genetic disorder, is considered the best prototype of endoplasmic reticulum (ER) diseases. Classical WS features are childhood-onset diabetes mellitus, optic atrophy, deafness, diabetes insipidus, neurological signs, and other abnormalities. Two causative genes (WFS1 and WFS2) have been identified. The transmission of the disease takes place in an autosomal recessive mode but autosomal dominant mutations responsible for WS-related disorders have been described. Prognosis is poor, death occurs at the median age of 39 years with a major cause represented by respiratory failure as a consequence of brain stem atrophy and neurodegeneration. The aim of this narrative review is to focus on etiology, pathogenesis and natural history of WS for an adequate patient management and for the discussion of future therapeutic interventions. MAIN BODY: WS requires a multidisciplinary approach in order to be successfully treated. A prompt diagnosis decreases morbidity and mortality through prevention and treatment of complications. Being a monogenic pathology, WS represents a perfect model to study the mechanisms of ER stress and how this condition leads to cell death, in comparison with other prevalent diseases in which multiple factors interact to produce the disease manifestations. WS is also an important disease prototype to identify drugs and molecules associated with ER homeostasis. Evidence indicates that specific metabolic diseases (type 1 and type 2 diabetes), neurodegenerative diseases, atherosclerosis, inflammatory pathologies and also cancer are closely related to ER dysfunction. CONCLUSIONS: Therapeutic strategies in WS are based on drug repurposing (i.e., investigation of approved drugs for novel therapeutic indications) with the aim to stop the progression of the disease by reducing the endoplasmic reticulum stress. An extensive understanding of WS from pathophysiology to therapy is fundamental and more studies are necessary to better manage this devastating disease and guarantee the patients a better quality of life and longer life expectancy.
format Online
Article
Text
id pubmed-6651977
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66519772019-07-31 Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives Pallotta, Maria Teresa Tascini, Giorgia Crispoldi, Roberta Orabona, Ciriana Mondanelli, Giada Grohmann, Ursula Esposito, Susanna J Transl Med Review BACKGROUND: Wolfram syndrome (WS), a rare genetic disorder, is considered the best prototype of endoplasmic reticulum (ER) diseases. Classical WS features are childhood-onset diabetes mellitus, optic atrophy, deafness, diabetes insipidus, neurological signs, and other abnormalities. Two causative genes (WFS1 and WFS2) have been identified. The transmission of the disease takes place in an autosomal recessive mode but autosomal dominant mutations responsible for WS-related disorders have been described. Prognosis is poor, death occurs at the median age of 39 years with a major cause represented by respiratory failure as a consequence of brain stem atrophy and neurodegeneration. The aim of this narrative review is to focus on etiology, pathogenesis and natural history of WS for an adequate patient management and for the discussion of future therapeutic interventions. MAIN BODY: WS requires a multidisciplinary approach in order to be successfully treated. A prompt diagnosis decreases morbidity and mortality through prevention and treatment of complications. Being a monogenic pathology, WS represents a perfect model to study the mechanisms of ER stress and how this condition leads to cell death, in comparison with other prevalent diseases in which multiple factors interact to produce the disease manifestations. WS is also an important disease prototype to identify drugs and molecules associated with ER homeostasis. Evidence indicates that specific metabolic diseases (type 1 and type 2 diabetes), neurodegenerative diseases, atherosclerosis, inflammatory pathologies and also cancer are closely related to ER dysfunction. CONCLUSIONS: Therapeutic strategies in WS are based on drug repurposing (i.e., investigation of approved drugs for novel therapeutic indications) with the aim to stop the progression of the disease by reducing the endoplasmic reticulum stress. An extensive understanding of WS from pathophysiology to therapy is fundamental and more studies are necessary to better manage this devastating disease and guarantee the patients a better quality of life and longer life expectancy. BioMed Central 2019-07-23 /pmc/articles/PMC6651977/ /pubmed/31337416 http://dx.doi.org/10.1186/s12967-019-1993-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Pallotta, Maria Teresa
Tascini, Giorgia
Crispoldi, Roberta
Orabona, Ciriana
Mondanelli, Giada
Grohmann, Ursula
Esposito, Susanna
Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title_full Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title_fullStr Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title_full_unstemmed Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title_short Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
title_sort wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651977/
https://www.ncbi.nlm.nih.gov/pubmed/31337416
http://dx.doi.org/10.1186/s12967-019-1993-1
work_keys_str_mv AT pallottamariateresa wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT tascinigiorgia wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT crispoldiroberta wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT orabonaciriana wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT mondanelligiada wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT grohmannursula wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives
AT espositosusanna wolframsyndromearareneurodegenerativediseasefrompathogenesistofuturetreatmentperspectives